Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)
- Citation:
- J Clin Oncol vol 39 (6_suppl) 154
- Meeting Instance:
- ASCO GU 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- 3697